Actualización de las recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón avanzado de célula no pequeña. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

López‐Ríos, Fernando; Castro, Javier de; Concha, Ángel; Garrido, Pilar; Gómez-Román, Javier; Isla, Dolores; Ramírez, José; Paz‐Ares, Luis; Sanz, Julián; Felip, Enriqueta

doi:10.1016/j.patol.2014.10.005

Cited by 4 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is now a reality that in patients with advanced NSCLC, not only pathological information but also predictive biomarker results are needed to enable treatment selection in some patient subgroups 15. As a result, accurate molecular diagnosis in patients with NSCLC is becoming increasingly important in routine clinical practice 10.…”

Section: Discussionmentioning

confidence: 99%

Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP)

et al. 2021

View full text Add to dashboard Cite

AimsThe aim of this study is to extend the analysis of the Lung Cancer Biomarker Testing Registry (LungPath), by analysing the techniques used in the determination of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1) and programmed death ligand-1 (PD-L1) for the diagnostic of patients with advanced non-small-cell lung cancer (NSCLC).MethodsInformation of the technique used for the determination of EGFR, ALK, ROS1 and PD-L1 was recorded from March 2018 to January 2019 from 44 centres, but only 34 centres matched with the 38 centres previously analysed, allowing to analyse the techniques used in 8970 matched determinations of EGFR, ALK, ROS1 and PD-L1. Therefore, a by-centre analysis studied the level of implementation of the techniques in the 44 centres, while a by-determination analysis made it possible to assess the overall frequency of the techniques used on the 9134 matched samples.ResultsBy-centre analysis showed that only 46.5% and 25.6% of the centres used reflex strategies for ALK and ROS1 determination, respectively. By-determination analysis showed that 94.4% of EGFR determinations were performed by PCR, 80.7% of ALK determinations were performed by IHC with clone D5F3, while 55.7% of ROS1 determinations were performed by IHC with clone D4D6. 22C3 were the PD-L1 clone more used (43.5%) followed by SP263 clone (31.1%).ConclusionsThe real-world evidence obtained from LungPath shows the effort of Spanish hospitals in performing biomarker determination in NSCLC with different methodologies despite that next-generation sequencing (NGS) utilisation in the year of the analysis was low. Biomarker determination results could be optimised with the incorporation of sequencing methods such as NGS in pathology departments.

show abstract

Section: Discussionmentioning

confidence: 99%

Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Para ello, el servicio de anatomía patológica establece un flujo de trabajo que permite un diagnóstico totalmente integrado. En los estudios con base morfológica, como la inmunohistoquímica o FISH (hibridación in situ), el anatomopatólogo ha de distinguir entre estructuras neoplásicas y sanas para garantizar un diagnóstico molecular correcto (López-Ríos et al, 2015). Para ello, se debe seleccionar mediante microscopio óptico el área más representativa de la lesión tumoral, considerando que dichas muestras presentan un tamaño reducido y diferenciación divergente o heterogeneidad.…”

Section: Problemática En La Detección De Mutacionesunclassified

Desarrollo de métodos integrados para la determinación de biomarcadores genéticos

Tejedor¹

View full text Add to dashboard Cite

Cáncer de pulmón no microcítico

Expósito

González

Castillo

et al. 2017

Medicine - Programa de Formación Médica Continuada Acreditado

View full text Add to dashboard Cite

Actualización de las recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón avanzado de célula no pequeña. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

Cited by 4 publications

References 50 publications

Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP)

Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP)

Desarrollo de métodos integrados para la determinación de biomarcadores genéticos

Cáncer de pulmón no microcítico

Contact Info

Product

Resources

About